1,2,10,11 RUNX3, runt-domain transcription factor, is a master regulator of gene expression in major developmental pathways. It acts as a tumor suppressor in many cancers but is oncogenic in certain tumors. We observed upregulation of RUNX3 mRNA and protein expression in nasal-type extranodal natural killer (NK)/T-cell lymphoma (NKTL) patient samples and NKTL cell lines compared to normal NK cells. RUNX3 silenced NKTL cells showed increased apoptosis and reduced cell proliferation. Potential binding sites for MYC were identified in the RUNX3 enhancer region. Chromatin immunoprecipitation-quantitative PCR revealed binding activity between MYC and RUNX3. Co-transfection of the MYC expression vector with RUNX3 enhancer reporter plasmid resulted in activation of RUNX3 enhancer indicating that MYC positively regulates RUNX3 transcription in NKTL cell lines. Treatment with a small-molecule MYC inhibitor (JQ1) caused significant downregulation of MYC and RUNX3, leading to apoptosis in NKTL cells. The growth inhibition resulting from depletion of MYC by JQ1 was rescued by ectopic MYC expression. In summary, our study identified RUNX3 overexpression in NKTL with functional oncogenic properties. We further delineate that MYC may be an important upstream driver of RUNX3 upregulation and since MYC is upregulated in NKTL, further study on the employment of MYC inhibition as a therapeutic strategy is warranted.
INTRODUCTION
Human runt-related transcription factor (RUNX) family is composed of three members including RUNX1, RUNX2 and RUNX3, are known as the developmental regulators and have been shown to be important in human cancers. 1 RUNX family is highly conserved in their runt homology domain, which is involved in the sequencespecific DNA binding and heterodimerization with the common co-factor CBFβ.
2 RUNX1 is essential for generation of hematopoietic stem cells and is involved in human leukemia.
2,3 RUNX2 is essential for skeletal development and has an oncogenic potential. 1, 4 RUNX3 is expressed in wider ranges of tissues and has multiple roles. Among others, RUNX3 is a major tumor suppressor of gastric, colon and many other solid tumors. 2, 5, 6 Inactivation of RUNX3 by hemizygous deletion, promoter hypermethylation, histone modification and protein mislocalization is frequently observed, suggesting a tumor suppressive role for RUNX3. [5] [6] [7] In addition to its well-known tumor suppressor role in human cancers, RUNX3 has also recently been reported to play an oncogenic role in a certain subset of cancers. Oncogenic properties of RUNX were first identified by retroviral activation screens in which all three murine RUNX genes were found to cooperate with MYC oncogene to promote leukemogenesis. 8 In basal cell carcinomas, RUNX3 was overexpressed in cancer cells compared to normal epidermis. 9 RUNX3 is also oncogenic in head and neck squamous cell carcinoma, ovarian cancer and Ewing sarcoma where overexpression of RUNX3 promoted proliferation and tumorigenesis. [10] [11] [12] Collectively, these findings suggest that RUNX3 can function as an oncogene and tumor suppressor in a cellular context-dependent manner.
Extranodal NK/T-cell lymphoma nasal-type (NKTL) is a rare and aggressive disease more frequent in Asia and South America than in Europe and North America and is characterized by a neoplastic proliferation of Epstein-Barr virus (EBV)-infected cytotoxic T and NK cells. 13 Although several recent studies have explored new treatment modalities for NKTL, the optimal therapy has still not been found. Interestingly, there have been several recent reports implicating the role of RUNX3 in the maturation pathway of NK cells and cytotoxic T-lymphocytes.
14 RUNX3 mediates transcriptional activation in cytotoxic T-and NK cells. Functional annotation of shared CD8+ T and NK RUNX3-regulated genes revealed enrichment for those involved in lymphocyte activation, proliferation, cytotoxicity, migration and cytokine production. 15 RUNX3 also regulates expression of Eomes and three cardinal markers of the effector cytotoxic T lymphocyte program including IFN-γ, perforin, and granzyme B, indicating a critical role of RUNX3 in the differentiation of NK and cytotoxic T-lymphocytes. 16 Interestingly, gene expression data from our previous study on NKTL revealed RUNX3 to be upregulated in tumor compared to normal NK cells.
In this study, we investigated the role of RUNX3 and demonstrated that RUNX3 is overexpressed in NKTL compared to normal NK cells and downregulation of RUNX3 results in increased apoptosis and reduced proliferation, supporting the role of RUNX3 as an oncogene in NKTL. We further deciphered the mechanisms of RUNX3 upregulation in NKTL and our data revealed that MYC plays a role in the transcriptional regulation of RUNX3 in NKTL. Targeted inhibition of MYC using smallmolecule inhibitor, JQ1, resulted in downregulation of MYC and RUNX3 with reduction in cell proliferation and increased cell death.
MATERIALS AND METHODS
Cell culture and NK cell isolation A panel of NKTL cells (KHYG-1, HANK-1, NK-YS, SNK-1 and SNK-6) were used in this study. Cell lines were incubated at 37°C in a humidified atmosphere of 5% CO 2 . The characteristics and the culture conditions are listed in the Supplementary Table S1 .
Highly pure untouched normal NK cells were isolated using an indirect magnetic labeling system by depletion of magnetically labeled cells from human peripheral blood mononuclear cells. (STEMCELL Technologies Inc., Vancouver, BC, Canada).
Immunohistochemistry and immunofluorescence
Four-μm sections from tissue microarray (TMA) blocks containing 38 samples of NKTL were stained for RUNX3 (1:500, 5G4 clone from Professor Yoshiaki Ito). The clinical and pathological data of the 38 NKTL samples were previously published and included in Supplementary Table S2 . 18 The immunohistochemical expression for RUNX3 was scored as a percentage of the total tumor cell population per 1-mm core diameter (400 × ). Positive expression for RUNX3 is defined as positive nuclear expression of RUNX3 in at least 50% of tumor cell population. We obtained the expression values of MYC from our previous study 17 
Flow cytometric analysis for apoptosis
The apoptotic cell death analyses were carried out using Annexin-V-APC and propidium iodide (PI) detection systems.
Cell proliferation analysis 
Cell viability analysis
Cell viability was determined using the MTS assay (Promega). The cells were incubated for 72 h and MTS reagent was then added into each well and incubated for 2 h at 37°C, followed by the absorbance reading at 490 nm using a microplate reader (TECAN Infinite 200 Pro, Zurich, Switzerland).
MYC Inhibition with JQ1 and Rescue in NKTL cells
The thieno-triazolo-1,4-diazepine (JQ1) compound used in assays was a kind gift from James Bradner (Dana-Farber Cancer Institute, MA, USA), and suspended in DMSO to a stock concentration (10 mM) and subsequently diluted to working concentrations as indicated for treatment assays. In order to assess if the cell death from JQ1 treatment can be rescued by overexpression of MYC, NKTL cells were transfected with pcDNA3-MYC or empty vector, respectively, and incubated overnight. The transfection efficiency was validated using NKTL cells (Supplementary Figure S1) . Transfected NKTL cells were treated with JQ1 for 48 h and processed for cell viability assays. Gene expression and western blotting was performed to assess MYC levels in the treated cells. See Supplementary Information for details of all methods and materials. Figure S2 ) and this may be due to alternatively spliced isoforms arising from differential usage of the two alternative RUNX3 promoters (P1 and P2) in tumor cells and/or mobility shift secondary to post-translational modifications, such as phosphorylation and ubiquitination. 19, 20 We further analyzed RUNX3 protein expression using immunohistochemistry on tissue microarray sections containing 38 reduction and a corresponding reduction in the protein expressions (Figures 2a and b) . Apoptosis assay revealed that RUNX3 depletion resulted in increased levels of apoptosis in all five NKTL cells with the effect most prominently seen in KHYG-1, HANK-1 and NK-YS. (Figure 2c and Supplementary Figure S3 ). In agreement with the apoptotic assay, the knockdown phenotype of the NKTL cells also displayed a substantial reduction in their proliferation rate, as illustrated by a decrease in their BrdU incorporation (Figure 2d) .
RESULTS

RUNX3 is overexpressed in NKTL
Recently, it has been shown in lung cancer mouse model that RUNX3 is necessary for the normal function of the p14 ARF -p53 pathway, which induces apoptosis and protects cells from oncogenic stimuli such as activated Ras and MYC. 21, 22 In this mouse model, Kras G12D induces RUNX3 expression causing p53 stabilization and tumor suppression, and RUNX3 inactivation by the mutation contributes to tumor development. 19 To clarify if the overexpression of RUNX3 is a consequence of deregulation of the p14 ARF -p53 pathway instead of RUNX3 acting as an oncogene, we sequenced the entire open reading frame of the p53 gene for mutation in five NKTL cell lines. Four of the five NKTL cell lines showed wild-type p53, indicating that the p14 ARF -p53 pathway inactivation by p53 mutation is an unlikely mechanism in NKTL (Supplementary Methods and Supplementary Table S4 ). We also demonstrated that the p53 signaling pathway is functionally intact. NKTL cells displayed normal functional p53 drug-induced responses as evidenced by the upregulation of total and phosphorylated p53 together with its downstream targets MDM2, p21, PUMA and NOXA following drug-induced genotoxic stress (Supplementary Methods and Supplementary Figures S4a  and b) . Furthermore, RUNX3 expression in NKTL is in the nucleus rather than cytoplasm where the protein undergoes degradation. 23 Together with our knockdown data, our results suggest that the overexpressed RUNX3 is active and functional in NKTL, thereby strengthening the postulation that RUNX3 overexpression is indeed oncogenic in NKTL.
Mechanism of RUNX3 overexpression in NKTL In order to understand the mechanism of RUNX3 deregulation in NKTL, we looked for mutation and recurrent copy-number changes as possible mechanisms for RUNX3 upregulation. However, amplification and gains involving genomic loci containing RUNX3 have not been detected in NKTL. 24, 25 Whole-exome sequencing on NKTL performed also did not detect any mutation of RUNX3.
26,27 Hence, we hypothesize that RUNX3 overexpression is transcriptionally modulated in NKTL.
MYC is involved in the transcriptional regulation of RUNX3 Data from murine retroviral insertional work had demonstrated that RUNX family of genes, including RUNX3, can act as a MYC-collaborating gene in the pathogenesis of thymic T-cell lymphoma in CD2-MYC transgenic mice. These proviral insertions induced overexpression of structurally intact RUNX gene products. 28, 29 In addition, we have found MYC to be activated in NKTL in our previous study. 17 When we compared the immunohistochemical protein expression of RUNX3 and MYC derived from our previous study, we found that cases of NKTL with high MYC protein expression also showed a significantly higher median expression of RUNX3 (P = 0.006; Figure 3a) , and there was a moderate correlation between RUNX3 and MYC protein expression using Spearman correlation analysis (r = 0.5, P = 0.001; Figure 3b and Supplementary Figure S5a) . Figure S5b) . Based on these findings, we investigated whether the upregulation of RUNX3 may be transcriptionally modulated by MYC.
To this end, we examined for potential binding activity between MYC and RUNX3 using MatInspector, which is a software tool that utilizes a large library of matrix descriptions for transcription factor binding sites to locate matches in DNA sequences. 30 We identified 3 potential binding sites for MYC in the RUNX3 enhancer (eR3) region (Supplementary Figure S6) . In addition, using Clustal Omega software, which is a sequence alignment tool used to identify regions of similarity that may indicate functional, structural and/or evolutionary relationship between two biological sequences, we found that the MYC binding sites in the eR3 sequences of human, mouse, dog, horse and chimpanzee show a high degree of similarity (Supplementary Figure S6) , suggesting that the MYC binding sites are evolutionarily conserved across different species and likely to play an in vivo regulatory role.
Next we evaluated whether MYC can induce the activity of RUNX3 enhancer in HeLa and NKYS cells. Co-transfection of the MYC expression vector with the RUNX3 enhancer reporter plasmid resulted in considerable activation of RUNX3 enhancer activity than the reference construct in HeLa (3-fold increase) and NK-YS (2.2-fold increase) cells (Figure 4a ). An increase in RUNX3 enhancer activity was not seen when the co-transfection was performed with the RUNX3 reporter construct where all three potential MYC binding sites were mutated, indicating that MYC transactivates RUNX3 enhancer in a DNA-binding-dependent manner (see Supplementary Methods for details).
We further examined whether MYC binds to the RUNX3 enhancer (eR3) using ChIP-qPCR assays in KHYG-1 and SNK-1 cells. Using an antibody directed against MYC, the immunoprecipitated chromatin was amplified using primers flanking the MYC binding sites in the RUNX3 enhancer. We observed a specific enrichment of genomic DNA fragments at the MYC Figure S7a) . There was a corresponding reduction in RUNX3 protein expression following knockdown of MYC in KHYG-1, HANK-1 and SNK-6 (Figure 4c ). However, when we knockdown RUNX3, MYC mRNA levels remained unaffected (Supplementary Figure S7b) . Collectively, these results indicate that MYC is upstream of RUNX3 and positively regulates RUNX3 transcription. However, we noticed that a large proportion of cases show marked RUNX3 overexpression without a corresponding upregulation of MYC (Figure 3b ), suggesting that MYC may not be a direct upstream regulator of RUNX3 in NKTL and other factors may be involved in the overexpression of RUNX3. Fold enrichment in the ChIP experiment represents the signal obtained after MYC immunoprecipitation followed by qPCR amplified by primer pairs that spanned the enhancer region. Fold enrichments were calculated by determining the IP efficiency (ratios of the amount of immunoprecipitated DNA to that of the input sample, i.e. percentage recovery) and normalized to the level observed at a control region, which was defined as 1. Control-1 and Control-2 denote the non-targeting negative controls while miR26a-2 and miR101 act as positive controls for the ChIP assay. There is a 3.3-fold (KHYG-1) and 6-fold (SNK-1) enrichment of genomic DNA fragments at the MYC binding sites compared to control pull-down sample, indicating binding of MYC to eR3. (c) Protein expressions of MYC and RUNX3 after MYC knockdown. NKTL cells were treated for 72 h and cell lysates were prepared for immunoblots for the MYC protein levels. RUNX3 expression profiles were analyzed post 96 h after MYC knockdown. Silencing of MYC sequentially deregulated RUNX3 expression in NKTL cells.
viability results, the treated cells also showed a dose-dependent induction of apoptosis, opening the possibility of MYC inhibition as a potential therapeutic strategy in NKTL but requires further evaluation.
Growth inhibition upon depletion of MYC by JQ1 treatment can be rescued by exogenous expression of MYC We next explored whether the depletion of MYC is responsible for the apoptosis induced by JQ1 treatment in malignant NKTL cells. To achieve this, MYC was transfected into SNK-1 and SNK-6 using an expression vector to bring about overexpression of MYC in the cell lines. This was followed by JQ1 treatment to assess if exogenous expression of MYC can prevent the growth reduction mediated by JQ1 treatment. Indeed, exogenous expression of MYC mRNA and protein (Figure 6a and b, left) in both control and JQ1-treated SNK-1 cell line was able to abort the decrease in cell viability and rescue the tumor cells from cell death compared to cells transfected with empty vector, with and without JQ-1 treatment (Figure 6c, left) . Similar results were observed in another NKTL cell line, SNK-6 (Figure 6a-c, right) . The rescue experiment results indicate that the JQ1-induced cell death in NKTL cells is in large part due to the decrease in MYC levels rather than an offtarget effect. Unlike MYC mRNA levels, which was not inhibited by JQ1 treatment following ectopic MYC expression (Figure 6a) , we noticed only minimal rescue effect on MYC protein levels (Figure 6b ). It is uncertain if this is due to the short half-life of MYC protein and variability in MYC degradation. 33 
DISCUSSION
It appears that both loss and gain of RUNX3 function can contribute to cancer development. The dual role of RUNX3 as a tumor suppressor and oncogene remains unclear but appears to be tissue dependent or organ specific rather than the histologic type of cancer 34 and indicates a complex mode of molecular activation and partnering.
In the recent years, there is increasing recognition that RUNX3 can also act as an oncogene in skin cancers including basal cell carcinomas (BCC), ovarian cancers, squamous cell carcinomas (SCC) of the head and neck, and Ewing sarcoma. [9] [10] [11] [12] [34] [35] [36] Moreover, high level expression of RUNX3 has been correlated with poor prognosis in a subset of acute myeloid leukemia carrying FLT3 mutations. 37 In BCC and SCC of head and neck, the overexpressed RUNX3 proteins are full-length and intact without mutation and fully functional. 9, 34 In gastric and other tumors, RUNX3 can be overexpressed due to protein mislocalization, 5, 38 which may be caused by MDM2-mediated ubiquitination and degradation of RUNX3 via p14 ARF -MDM2 surveillance pathway. 21 However, when RUNX3 transcription factor is mislocalized to the cytoplasm, it is in an inactive state and unlikely to function as an oncogene. 5, 38 Importantly, our data demonstrate that RUNX3 overexpression in NKTL is functionally active and shows oncogenic phenotype. First, RUNX3 is overexpressed in the tumor nuclei of NKTL, and not mislocalized to the cytoplasm where it may be inactivated. Second, knockdown of RUNX3 resulted in an increase in apoptosis and reduction in proliferation. Third, the lack of p53 mutation and an intact p53 pathway in the NKTL cell lines excludes the possibility that the overexpression of RUNX3 is as a consequence of deregulation of RUNX3-p14 ARF -p53 pathway. 39 Thus, our findings have uncovered a crucial and novel role of RUNX3 in promoting viability and proliferation. We have also demonstrated the upregulation of RUNX3 in the majority of highgrade B-cell lymphomas and peripheral T-cell lymphomas (Supplementary Table S5 and Supplementary Figure S9) , suggesting that the oncogenic role of RUNX3 may also be operational in other lymphoid malignancies and warrants further investigation.
While there has been a profusion of publications describing the role of RUNX3 as a tumor suppressor in a large variety of human cancers, the role of RUNX3 as an oncogene and the mechanisms of RUNX3 upregulation are poorly understood. [9] [10] [11] [12] 34, 36 Notably, we have demonstrated in this study that the oncogenic role of RUNX3 is transcriptionally regulated by MYC in NKTL. This is in line with data implicating the RUNX genes as MYC collaborating genes whereby RUNX targeting by retroviruses in T-or B-lymphoid cells have been identified in transgenic models harboring MYC. 28, 29, 40 Furthermore, reciprocal experiment in which CD2-RUNX2 mice were infected with murine leukemia virus revealed a major bias towards targeting of MYC family genes in the resultant T-cell lymphomas, again suggesting a preferential relationship in oncogenic collaboration between RUNX and MYC. 41 Although the precise mechanism of this collaboration remains unclear, it has been postulated that the resultant ectopic expression of RUNX isoforms contribute to lymphomagenesis by causing upregulation of target genes, such as T-cell receptor (TCR) complex genes and CD3ε. 29 Activation of TCR/CD3 expression is a crucial event in T-cell development 42 and transcriptional stimulation of the component genes may promote cell transit through growth or differentiation checkpoints or enabling survival of cells carrying TCRs with aberrant affinity for major histocompatibility complex. 29 MYC can be upregulated in cancers due to multiple mechanisms, including chromosomal translocation, gene amplification, mutation of upstream signaling pathways, and mutation that enhance the stability of the protein. Although MYC is often overexpressed in NKTL, neither amplification nor mutation of MYC was found in NKTL. 43 MYC is a transcriptional target of the EBV proteins EBNA2 44 and LMP1. 45 Since NKTL shows EBV latency pattern II characterized by absence of EBNA-2 and presence of LMP-1, 46 it is interesting to postulate that the activation of MYC in NKTL could be through the activity of an EBV-related protein, such as LMP1. 17 This would be consistent with the importance of EBV infection in the pathogenesis of NKTL. Another mechanism of MYC overexpression in NKTL may be via the phosphorylation activation of STAT3 since MYC is a known target of STAT3 transcriptional activity. 24, 47, 48 Besides regulating the transcriptional activation of RUNX3, data from our previous study demonstrated that MYC also upregulates EZH2 by inducing repression of its regulatory microRNAs in NKTL. 49 These results are consistent with MYC being a master regulator of diverse cellular functions and, hence, the proposition that MYC functions as a universal amplifier of gene expression rather than an on-off specifier of distinct transcriptional program(s). 50 Nevertheless, this proposal remains a subject of contention as regulation of distinct subsets of genes by MYC have also been demonstrated. 51, 52 In this study, we have demonstrated that MYC is involved in the transcriptional regulation of RUNX3 in NKTL. However, whether this is a result of MYC directly and specifically upregulating RUNX3 or a phenomenon of indirect amplification of global transcripts via downstream effects of MYC-induced subsets of genes require further characterization.
MYC is long considered a compelling therapeutic target because of its diverse role in human malignancies. However, pharmacologic inhibition of MYC function has proven challenging because of both the diverse mechanisms driving its aberrant expression and the challenge of disrupting protein-DNA interactions. Since MYC is activated in NKTL from our previous study, 17 we explored a novel compound, JQ1, which is able to reduce MYC transcription and reported to be therapeutically effective in preclinical animal models. 31, 32, 53 BET bromodomain inhibition by JQ1 confers a selective repression of transcriptional networks induced by c-MYC and the anti-tumor effect of JQ1 is not accompanied by a nonspecific, toxic effect on all hematopoietic cells. 32 Our findings with JQ1 treatment demonstrate that pharmacologic inhibition of MYC is achievable in NKTL cell lines through targeting BET bromodomains, resulting in downregulation of RUNX3, induction of apoptosis and reduced cell viability. This opens the possibility of targeting MYC as a potential therapeutic strategy in NKTL. Furthermore, the development of novel therapeutic strategies geared towards the modulation of MYC expression, either alone or in combination with other therapies, may be of potential therapeutic significance for aggressive and difficult to treat tumors, such as NKTL.
